Laboratory Medicine - Medical Biopathology: UEMS Section
6.3K views | +0 today
Follow
Laboratory Medicine - Medical Biopathology: UEMS Section
Laboratory Medicine at the Clinical Interface
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Laboratory Medicine and Medical Biopathology

is the new name of the UEMS section.

http://www.uems-slm.org/uems/

Laboratory Medicine is the name of a medical specialty where specialists are involved in medical diagnosis using laboratory assays to characterize molecular and cellular parameters in blood, biological fluids and tissues;

It is called also clinical pathology.

This page was opened in collaboration with the working group of EFLM dedicated to Distance Learning and e-Learning

Gilbert C FAUREs insight:

covering disciplines such as

 

(Biochemistry http://www.scoop.it/search?q=biochemistry)

 

Haematology

http://www.scoop.it/t/hematology

 

(Microbiology http://www.scoop.it/search?q=microbiology )

 

Immunology

http://www.scoop.it/t/immunology

 

(Genetics http://www.scoop.it/search?q=genetics)

some already covered by the curator of this topic

 

check also

http://www.scoop.it/t/autoimmunity

for autoimmune diseases diagnostic tools

 

CHECK for COVID-19

https://www.scoop.it/topic/medical-biopathology-and-laboratory-medicine/?&tag=covid-19

 50 relevant papers on tests

 

 

No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials | Oxford Immunotec North America

UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials OXFORD, United Kingdom and MARLBOROUGH, Mass., October 22, 2020 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has been selected to provide T cell testing to the UK Vaccines Taskforce, a body formed by the UK Government to assess the suitability of vaccines for use in the UK population. Oxford Immunotec was chosen in this competitive process for its expertise in T cell measurement and its unique ability to provide T-SPOT® technology, the only globally regulated ELISPOT platform, currently used clinically for identifying T cells made in response to another respiratory pathogen responsible for Tuberculosis. The award includes the measurement of the magnitude of the SARS-CoV-2 protein-specific T cell response using the company’s new T-SPOT® Discovery SARS-CoV-2 assay and is recognition of the company’s ability to deliver clinical grade, consistent and reproducible diagnostic products. T cells are becoming increasingly recognised for their role in SARS-CoV-2 infection and immunity; measuring the presence and size of any T cell response can give adjunctive information to that available by serology. Consequently, the UK Vaccines Taskforce is including T cell analysis in COVID vaccine trials. Kate Bingham, Chair of the UK Government’s Vaccines Taskforce said; “The UK Vaccines Taskforce is delighted to be partnering Oxford Immunotec, an experienced team who are responsible for running the Vaccines Taskforce T cell tests to assess the immunogenicity of COVID-19 vaccines. It is important to be able to assess the different vaccines head-to-head and the T cell response is part of our portfolio of accredited assays that we are employing for cross comparisons.” Oxford Immunotec’s T-SPOT technology platform enables the easy centralisation of fresh blood samples from different study locations, and highly standardised measurement of the T cell response. These attributes are essential in later stage large-scale vaccine trials, and will facilitate longitudinal studies and comparisons between trials. The UK Business Secretary Alok Sharma said; “T cell testing is crucial in our fight against coronavirus, helping us to assess the effectiveness of vaccine candidates undergoing trials by improving our understanding of people’s immune responses. Today we are partnering with Oxford Immunotec and providing up to £3 million investment so that they can provide this critical testing required for vaccine trials, supporting the development and regulatory approval of the most promising candidates.” Peter Wrighton-Smith, CEO of Oxford Immunotec, said; “We are thrilled that our expertise and proven track record in delivering T cell measurement tools have been recognised by the UK Vaccines Taskforce.” Peter went on to say, “We are excited to assist the UK government’s vaccination effort and to assist in continued discovery of the role that T cells play in the response and immunity to SARS-CoV-2.” T-SPOT Discovery SARS-CoV-2 is for research use only, not for use in diagnostic procedures Not all products are available in all regions, please contact us for information on availability in any specific country For further information visit: http://go.oxfordimmunotec.com/t-spot_discovery_SARS_CoV-2 About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world’s largest cause of death from infectious disease. The Company is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com About T-SPOT Discovery SARS-CoV-2 Oxford Immunotec has been developing and strengthening its expertise in T cell measurement for over 15 years since the introduction of its T-SPOT technology in the field of TB diagnostics. In that time, we have taken the classic ELISPOT technique and developed it into the world leading proprietary T-SPOT technology platform we now use to measure T cell immune responses, improving performance, standardising results, and streamlining the workflow. This high performance is ensured by our regularly audited manufacturing facility operating to our rigorous quality management system. The T-SPOT.TB test, an in vitro diagnostic (IVD) test using the T-SPOT technology platform, has been granted regulatory approval for clinical diagnostic use in over 50 countries, including US, EU, Japan and China. The research use-only T-SPOT Discovery SARS-CoV-2 assay uses this same T-SPOT technology to allow SARS-CoV-2-specific T cells to be detected and enumerated. The optimized antigen mix used in the test is based on SARS-CoV-2 structural proteins and allows the maximum breadth of the immune response to be measured. The Company’s single antigen-per-well approach allows specific information about the immune response to different SARS-CoV-2 antigens to be gathered in parallel. Sample processing can be centralised whilst still enabling testing on fresh (rather than frozen) blood, using the Company’s T-Cell Xtend® reagent (32 hr room temperature (RT) sample stability) or T-Cell Select™ reagent (54 hr RT sample stability – automated processing). The T-Cell Select reagent kit also allows for automation and therefore accommodates variations in scale – automation solutions are available for low, medium and high throughput settings. About the UK Vaccines Task Force The UK Vaccines Task Force has been commissioned to ensure the swift and safe implementation of a COVID vaccination in the UK. It is led by the UK’s Chief Scientific Adviser Sir Patrick Vallance and Deputy Chief Medical Officer Professor Jonathan van Tam. Chaired by Kate Bingham, it brings together the efforts of both large Pharma and academia under one umbrella. Not only does the UK Vaccines Taskforce drive vaccine development, but it will also review regulations and facilitate the rapid scale up of manufacturing, so that when a vaccine becomes available, it can be produced quickly and safely, in mass quantities, to ensure the protection of the UK population and smooth the pathway to the full reopening of the UK economy. A number of large pharmaceutical companies are working with the UK vaccine task force to achieve these goals including, Astra Zeneca, BioNTech, Pfizer, GlaxoSmithKline and Sanofi Pasteur, as well as academic institutions such as Oxford University and Imperial College London. T-SPOT, the Oxford Immunotec logo, T-Cell Xtend, T-Cell Select and T-SPOT Discovery are trademarks of Oxford Immunotec Limited. Forward-Looking Statements Certain statements in this press release constitute forward-looking statements within the meaning of applicable U.S. and U.K. laws and regulations, including under the U.S. Private Securities Litigation Reform Act of 1995. Any statements contained herein which do not describe historical or current facts, including beliefs that measuring T cells may be particularly important in several aspects of vaccine research, including before vaccination, during vaccine trials and clinical trial follow-up; the belief that the T cell response plays an important role in control of the virus independently to antibodies; the belief that T cell response might be more long lived than the antibody response; the belief that T cell response may help our understanding of the presence of immunity during clinical trial recruitment; the belief that T cell testing may help our understanding of the efficacy of new vaccines; and beliefs about the Company’s expertise and positioning to benefit the UK Vaccines Task Force constitute forward-looking statements. Any forward-looking statements are based on our management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the possibility that measuring T cells in any aspect of vaccine research may be not be as important as expected, T cell response might not play as important of a role as expected in control of the virus independently to antibodies, T cell response might not be as long lived as expected, T cell response may not help understanding of the presence of immunity during clinical trial recruitment, T cell testing may not help our understanding of the efficacy of new vaccines, the ability to execute on the development of T cell testing for SARS-CoV-2 infection and the parties’ ability to deliver on the expected benefits of the partnership and UK Vaccines Task Force, as well as those other risks and uncertainties described in Oxford Immunotec’s filings with the U.S. Securities and Exchange Commission (the “Commission”), including the Company’s Annual Report on Form 10-K for the year-ended December 31, 2019 and its Quarterly Report on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, and in any other reports it files with the Commission, including any other Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Oxford Immunotec’s filings with the Commission are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the Commission’s website, www.sec.gov. Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law. For Media and Investor Inquiries: Amy Bickell Oxford Immunotec Tel: +44 1235 442796 abickell@oxfordimmunotec.com
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Fecal Microbiota Transplantations: Where Are We, Where Are We Going, and What Is the Role of the Clinical Laboratory? | AACC.org

Fecal Microbiota Transplantations: Where Are We, Where Are We Going, and What Is the Role of the Clinical Laboratory? | AACC.org | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
In this Clinical Chemistry podcast, Drs. Eric Ransom and Andrew Reinink discuss their article from the April 2020 issue entitled "Fecal Microbiota Transplantations: Where Are We, Where Are We Going, and What Is the Role of the Clinical Laboratory?
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Reliability of Laboratory-Developed Tests Called Into Question

Reliability of Laboratory-Developed Tests Called Into Question | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
A recent HHS announcement addressed all LDTs, including those used for the diagnosis and treatment of patients with cancer.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Immunology and Pathology partnership announced to run training days for trainee clinical scientists — News

Immunology and Pathology partnership announced to run training days for trainee clinical scientists — News | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
The NSHCS facilitates and supports the education, training and development of healthcare scientists.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Ten Important Blood Tests Every Adult Need To Take Annually | Blog

Ten Important Blood Tests Every Adult Need To Take Annually | Blog | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
Here is a list of ten blood tests that has to be taken at least once in a year to monitor the general health of your body and for early detection of diseases.
Gilbert C FAUREs insight:

no comment

No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Most Talked About Articles of 2020 | Laboratory Medicine

Most Talked About Articles of 2020 | Laboratory Medicine | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
Enjoy reading Lab Medicine’s most talked about articles of 2020.Whether on Twitter, Facebook, the news, or elsewhere, these articles have received special atte...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory - Siriez - - International Journal of Laboratory Hem...

Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory - Siriez - - International Journal of Laboratory Hem... | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
There is a laboratory and clinical need to know the impact of direct oral anticoagulants (DOACs) on diagnostic tests to avoid misinterpretation of results. Although the regulatory labellin
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

MSACL - Annual Congress on Mass Spectrometry & Advances in the Clinical Lab

MSACL - Annual Congress on Mass Spectrometry & Advances in the Clinical Lab | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
MSACL is a non-profit association committed to the advancement of mass spectrometry and the development of new technologies to enhance patient care through education and training of practitioners, physicians, laboratory scientists, industrial scientists, and health care professionals.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

ESCMID: Practical Workshops

ESCMID - European Society of Clinical Microbiology and Infectious Diseases 2008...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Educate me - UK NEQAS | External Quality Assessment Services

Educate me - UK NEQAS | External Quality Assessment Services | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
UK NEQAS is a charitable consortium of external quality assessment laboratories, evolved from NHS services in the UK. Educate me about how UK NEQAS works.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

COVID-19 and the Path to Immunity | Allergy and Clinical Immunology | JAMA | JAMA Network

COVID-19 and the Path to Immunity | Allergy and Clinical Immunology | JAMA | JAMA Network | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
This Viewpoint reviews what is known about acute and long-term B-cell, antibody, and T-cell responses to SARS-CoV-2 infection and explains how each are implicated in vaccine candidates likely to be effective and durably protective again COVID-19.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

High-Impact Articles | Laboratory Medicine

High-Impact Articles | Laboratory Medicine | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
The latest Journal Citation Reports (Source Clarivate, 2020) have recently been released and have revealed that the 2019 Impact Factor for L...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Antibody tests for identification of current and past infection with SARS‐CoV‐2 - Deeks, JJ - 2020 | Cochrane Library

Antibody tests for identification of current and past infection with SARS‐CoV‐2 - Deeks, JJ - 2020 | Cochrane Library | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
500 The Cochrane Library appears to be unavailable to you at the moment. This could be due to maintenance activity or an unexpected issue. Please contact Customer Support for assistance.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Journal of Clinical Pathology and Laboratory Medicine | Home

Journal of Clinical Pathology and Laboratory Medicine | Home | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
Journal of Clinical Pathology and Laboratory Medicine...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to six months post disease onset - Figueiredo‐Campos - - European Journal of Immunology

Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to six months post disease onset - Figueiredo‐Campos - - European Journal of Immunology | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
SARS‐CoV‐2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia – COVID‐19 – but may remain mild or asymptomatic. To understand the continuing spread of the virus, to de...
No comment yet.
Suggested by LIGHTING
Scoop.it!

Lab Culture

Lab Culture | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
Lab Culture is ASLM’s magazine for laboratory medicine in Africa. Dedicated to bringing timely, informative, inspirational articles relevant to the unique challenges faced by African laboratories, Lab Culture seeks to be Africa’s premiere resource for laboratory professionals and other stakeholders working on or with the continent. Published four times a year as a digital edition, Lab... Read More
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

virtual.MEDICA presents specialist topics in laboratory medicine

virtual.MEDICA presents specialist topics in laboratory medicine | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
virtual.MEDICA presents specialist topics in laboratory medicine   OCT 13, 2020 This year’s virtual.MEDICA presents specialist topics in laboratory medicine and reflects the significance of this sector in the fight against the coronavirus pandemic. How can diagnoses be given even faster and more securely, aided by cutting-edge scientific findings? How can a multitude of information be linked and concatenated to elicit new therapy options? The MEDICA LABMED FORUM seeks to respond to these and many other questions. This year, the MEDICA LABMED FORUM will offer a high-profile programme with top speakers, which is free for registered online visitors. This programme will be held digitally due to the pandemic and can be accessed via the Conference Area in virtual.MEDICA (https://virtual.MEDICA.de) on all days of the trade fair (16–19 November 2020). The sessions in the forum focus on microbiology and infectious diseases, cardiology and oncology, and, of course, COVID-19. In addition, young scientists and the industry glimpse into the future together and present promising trends in laboratory medicine. The organiser of this series of events is Professor Georg Hoffmann from Trillium, the medical publisher, in cooperation with the German Heart Centre Munich (DHM). Read more here. Other News Non-tuberculous mycobacterial pulmonary disease NEWS / OCT 13, 2020 DNA and RNA extraction, now with automated option NEWS / OCT 13, 2020 Cellular pathology: beyond the next generation NEWS / OCT 13, 2020 Support for near-patient testing in treatment-resistant schizophrenia NEWS / OCT 13, 2020 Helping diagnostic laboratories scale up liquid handling NEWS / OCT 08, 2020 High-sensitivity troponin tests for early rule out of NSTEMI NEWS / OCT 08, 2020 Pathology contract for Guy's, St Thomas’ and King’s College hospitals NEWS / OCT 06, 2020 Quick and reliable endotoxin and β-glucan testing NEWS / OCT 06, 2020 Detection of circulating SARS-CoV-2 neutralising antibodies NEWS / OCT 06, 2020 Publication of NHS England diagnostics report welcomed by BIVDA NEWS / OCT 05, 2020
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Dr. Barnali Das posted on LinkedIn

Dr. Barnali Das posted on LinkedIn | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
Cover story TechAgappe Oct-Dec, 2020 Edition: Race against Covid 19: redefines the role of laboratory physicians..This article is my tribute to ou
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Laboratory tests commonly used in complementary and alternative medicine: a review of the evidence

Laboratory tests commonly used in complementary and alternative medicine: a review of the evidence | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
It is increasingly easy for the general public to access a wide range of laboratory tests. Tests can be ordered online with little or no input from a health professional.The complementary and alternative medicine (CAM) community promote and sell a wide range of tests, many of which are of dubious...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Study: Head to head comparison of 5 assays used to detect SARS-CoV-2 antibodies

Study: Head to head comparison of 5 assays used to detect SARS-CoV-2 antibodies | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
New research being presented at the ESCMID Conference on Coronavirus Disease (ECCVID, online 23-25 September) shows that, in a head-to-head comparison of five tests used to detect SARS-CoV-2 antibodies (known as 'immunoassays'), an assay manufactured by Siemens and one developed by an academic...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Register | AACC.org

Register | AACC.org | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
Registration for the virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo is open through December 17....
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

CPDLMS – The NLA Training Site

CPDLMS – The NLA Training Site | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
Welcome to the National Laboratory Association’s (NLA-SA) new website for continuing professional development (CPD) and training. The purpose of this web site is to provide a resource for both CPD activities as well as on-line training courses. Online CPD activities: The objective of this category is provide users with various online activities that will enable Metrologists who are MetCert Certified to complete these activities online. Successful completion will count towards CPD points that are required for re-certification in terms of the CPD requirements of MetCert. Online training: The NLA-SA’s successful implementation of a Certification Scheme for Persons, viz. MetCert, has attracted interest in various other areas. In some cases  online training will be provided. The first of these is for Stack Emission Testers. The complete details of how to become certified can be found on the main NLA-SA web site. In order to use the site users will need to register and and in some cases additional costs will be incurred.
No comment yet.
Rescooped by Gilbert C FAURE from Coronavirus - COVID 19 HAS veille
Scoop.it!

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
A new technology for COVID-19 detection has become available that is much simpler and faster to perform that currently-recommended nucleic acid amplification tests (NAAT), like PCR. This method relies on direct detection of SARS-CoV-2 viral proteins in nasal swabs and other respiratory secretions using a lateral flow immunoassay (also called an RDT) that gives results in < 30 minutes. Though these antigen detection RDTs (Ag-RDTs) are substantially less sensitive than NAAT, they offer the possibility of rapid, inexpensive and early detection of the most infectious COVID cases in appropriate settings. Acknowledging the inadequacy of current data on the performance and operational utility of these tests, this document seeks to provide guidance to countries on considerations for integration into COVID outbreak management programs.

Via HAS-veille
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Evaluation of COVID‐19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays - White - - International Journal of Laboratory Hematology


Introduction
Patients with COVID‐19 are known to have a coagulopathy with a thrombosis risk. It is unknown whether this is due to a generalized humoral prothrombotic state or endothelial factor
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Thieme E-Books & E-Journals - Journal of Laboratory Physicians / Issue

Thieme E-Books & E-Journals - Journal of Laboratory Physicians / Issue | Laboratory Medicine - Medical Biopathology: UEMS Section | Scoop.it
Thieme E-Books & E-Journals...
Gilbert C FAUREs insight:

Journal of Laboratory Physicians (JLP) is the official journal of The Indian Association of Laboratory Physicians (IALP), a professional, literary, non-commercial, organization founded in 1990. It aims to promote the laboratory sciences in all hemispheres. With the tremendous advancements in clinical care and developments in science, diagnostic branches like pathology, microbiology, immunology, biochemistry and radiology have come into forefront in patient management. Globally, there has been an increase in patients on life support systems, immunocompromised patients, preterm and geriatric patients, adding a new dimension to diagnostic medicine. Having this aim, the association started JLP in 2009, as a bi-annual journal. It became a quarterly publication in 2017.

No comment yet.